123 related articles for article (PubMed ID: 30268049)
1. Design, synthesis and biological evaluation N
Xing L; Jing T; Zhang J; Guo M; Miao X; Jiang F; Zhai X
Bioorg Chem; 2018 Dec; 81():689-699. PubMed ID: 30268049
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
3. 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228 cells.
Han M; Shen J; Wang L; Wang Y; Zhai X; Li Y; Liu M; Li Z; Zuo D; Wu Y
Chem Biol Interact; 2018 Mar; 284():24-31. PubMed ID: 29458018
[TBL] [Abstract][Full Text] [Related]
4. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives.
Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X
Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1.
Wang Y; Zhang G; Hu G; Bu Y; Lei H; Zuo D; Han M; Zhai X; Gong P
Eur J Med Chem; 2016 Nov; 123():80-89. PubMed ID: 27474925
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation.
Geng K; Xia Z; Ji Y; Zhang RR; Sun D; Ai J; Song Z; Geng M; Zhang A
Eur J Med Chem; 2018 Jan; 144():386-397. PubMed ID: 29288940
[TBL] [Abstract][Full Text] [Related]
7. Identification of highly potent 2,4-diarylaminopyrimidine analogs of a typical piperidinyl-4-ol moiety as promising antitumor ALK inhibitors.
Liu S; Wang F; Yang J; Su G; Cao Z; Shan M; Zhai X
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300416. PubMed ID: 37737557
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.
Geng K; Liu H; Song Z; Zhang C; Zhang M; Yang H; Cao J; Geng M; Shen A; Zhang A
Eur J Med Chem; 2018 May; 152():76-86. PubMed ID: 29698859
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
14. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors.
Wang L; Xu S; Chen X; Liu X; Duan Y; Kong D; Zhao D; Zheng P; Tang Q; Zhu W
Bioorg Med Chem; 2018 Jan; 26(1):245-256. PubMed ID: 29203143
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
18. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors.
Zhang HQ; Gong FH; Li CG; Zhang C; Wang YJ; Xu YG; Sun LP
Eur J Med Chem; 2016 Feb; 109():371-9. PubMed ID: 26826581
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.
Kang GA; Lee M; Song D; Lee HK; Ahn S; Park CH; Lee CO; Yun CS; Jung H; Kim P; Ha JD; Cho SY; Kim HR; Hwang JY
Bioorg Med Chem Lett; 2015 Sep; 25(18):3992-8. PubMed ID: 26235945
[TBL] [Abstract][Full Text] [Related]
20. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
